Risk factors, clinical features, and outcome of Pseudomonas aeruginosa bacteremia in patients with hematologic malignancies: a case-control study

Am J Infect Control. 2013 Jun;41(6):527-30. doi: 10.1016/j.ajic.2012.07.012. Epub 2012 Dec 7.

Abstract

Background: We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source.

Methods: We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies.

Results: Forty-two episodes of P aeruginosa bacteremia were identified. At presentation, 26 patients (62%) had pneumonia and 9 patients (21%) were in shock. Twenty-five patients (60%) were aplastic. The clinical cure rate was 40%. Comparing the 42 cases with 84 matched controls identified the following independent risk factors for P aeruginosa bacteremia: hospitalization in the previous 3 months (odds ratio [OR], 12.84; 95% confidence interval [CI], 2.98-55.18), antibiotic therapy in the previous 3 months (OR, 5.34; 95% CI, 2.14-13.30), receipt of ceftriaxone in the previous 3 months (OR, 2.38; 95% CI, 1.08-5.27), receipt of aminoglycosides in the previous 3 months (OR, 6.65; 95% CI, 1.15-38.25) and receipt of fluoroquinolones in the previous 3 months (OR, 3.22; 95% CI, 1.48-7.00).

Conclusions: Local antibiotic therapy algorithms were modified to decrease prescriptions of ceftriaxone and combination therapy with aminoglycosides and fluoroquinolones in an effort to decrease the risk of P aeruginosa bacteremia.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Algorithms
  • Aminoglycosides / administration & dosage
  • Anti-Bacterial Agents / administration & dosage
  • Bacteremia / diagnosis
  • Bacteremia / drug therapy*
  • Bacteremia / epidemiology*
  • Case-Control Studies
  • Ceftriaxone / administration & dosage
  • Child
  • Comorbidity
  • Female
  • Fluoroquinolones / administration & dosage
  • Hematologic Neoplasms / epidemiology*
  • Hematologic Neoplasms / microbiology
  • Humans
  • Male
  • Middle Aged
  • Pseudomonas Infections / diagnosis
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / epidemiology*
  • Pseudomonas aeruginosa / drug effects*
  • Risk Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Ceftriaxone